Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
114 studies found for:    30607
Show Display Options
Rank Status Study
1 Active, not recruiting Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Conditions: Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Sunitinib Malate;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
2 Active, not recruiting Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001;   Drug: sunitinib
3 Active, not recruiting
Has Results
Study of Participants With Advanced Non-Small Cell Lung Cancer
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Bevacizumab
4 Completed
Has Results
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: Bevacizumab;   Drug: Abraxane
5 Completed A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small-cell Lung Carcinoma
Intervention: Drug: Tarceva (erlotinib HCl)
6 Terminated
Has Results
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Sorafenib Escalated Dose;   Drug: Sorafenib Standard Dose
7 Completed Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: Ezatiostat Hydrochloride
8 Unknown  Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Condition: Breast Cancer
Intervention: Drug: Bevacizumab (drug), Herceptin (drug)
9 Terminated
Has Results
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: doxorubicin HCl liposome
10 Recruiting Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Stage IIIB;   Non-Small-Cell Lung Cancer Stage IV;   Non-Small-Cell Lung Cancer Metastatic;   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Biological: bavituximab;   Drug: Docetaxel;   Other: Placebo (for bavituximab)
11 Active, not recruiting A Study of Chemotherapy and Ramucirumab Versus (vs.) Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Docetaxel;   Biological: Ramucirumab;   Drug: Placebo
12 Active, not recruiting A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Condition: Cancer
Interventions: Drug: pazopanib;   Drug: placebo
13 Completed Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Condition: Locally Recurrent or Metastatic Breast Cancer
Interventions: Drug: Imetelstat sodium;   Drug: Bevacizumab;   Drug: Paclitaxel
14 Active, not recruiting
Has Results
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Condition: Melanoma
Interventions: Drug: GSK1120212;   Drug: Chemotherapy
15 Completed
Has Results
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Biological: Cetuximab;   Drug: Docetaxel
16 Recruiting A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: LY2875358;   Drug: Erlotinib
17 Recruiting Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Condition: Tumor Pathway Activations Inhibited by Dovitinib
Intervention: Drug: Dovitinib (TKI258)
18 Not yet recruiting Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: nab-paclitaxel IV;   Drug: CC-486
19 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
20 Terminated DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
Condition: Prostate Cancer
Interventions: Drug: calcitriol;   Drug: docetaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years